EP0489846A4 - Antisense oligonucleotides to c-abl proto-oncogene - Google Patents

Antisense oligonucleotides to c-abl proto-oncogene

Info

Publication number
EP0489846A4
EP0489846A4 EP19900913911 EP90913911A EP0489846A4 EP 0489846 A4 EP0489846 A4 EP 0489846A4 EP 19900913911 EP19900913911 EP 19900913911 EP 90913911 A EP90913911 A EP 90913911A EP 0489846 A4 EP0489846 A4 EP 0489846A4
Authority
EP
European Patent Office
Prior art keywords
oncogene
antisense oligonucleotides
abl proto
proto
abl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900913911
Other versions
EP0489846A1 (en
Inventor
Bruno Calabretta
Alan M. Gewirtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of EP0489846A1 publication Critical patent/EP0489846A1/en
Publication of EP0489846A4 publication Critical patent/EP0489846A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP19900913911 1989-09-01 1990-08-29 Antisense oligonucleotides to c-abl proto-oncogene Withdrawn EP0489846A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US402383 1982-07-27
US40238389A 1989-09-01 1989-09-01

Publications (2)

Publication Number Publication Date
EP0489846A1 EP0489846A1 (en) 1992-06-17
EP0489846A4 true EP0489846A4 (en) 1992-06-24

Family

ID=23591651

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900913911 Withdrawn EP0489846A4 (en) 1989-09-01 1990-08-29 Antisense oligonucleotides to c-abl proto-oncogene

Country Status (5)

Country Link
EP (1) EP0489846A4 (en)
JP (1) JPH05500217A (en)
AU (1) AU646643B2 (en)
CA (1) CA2065294A1 (en)
WO (1) WO1991003260A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
AU3129993A (en) * 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy
WO1994010302A1 (en) * 1992-10-29 1994-05-11 Boehringer Mannheim Gmbh Amplifiable vector against hiv replication
US6080851A (en) * 1992-12-04 2000-06-27 American Home Products Corporation Ribozymes with linked anchor sequences
EP0706573A1 (en) * 1993-07-09 1996-04-17 The Institute Of Cancer Research Protein tyrosine kinase and ligands thereof
AU6906396A (en) * 1995-08-30 1997-03-19 Arch Development Corporation Methods and compositions including dna damaging agents and tyrosine kinase inhibitors or activators
US20020068709A1 (en) * 1999-12-23 2002-06-06 Henrik Orum Therapeutic uses of LNA-modified oligonucleotides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3742049A1 (en) * 1987-12-11 1989-06-22 Theurer Karl Eugen Preparation and use of vaccines and diagnostic aids for viral diseases and cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3742049A1 (en) * 1987-12-11 1989-06-22 Theurer Karl Eugen Preparation and use of vaccines and diagnostic aids for viral diseases and cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 85, August 1988, WASHINGTON US pages 5698 - 5702; KAWASAKI, E.S. ET AL.: 'Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro' *
SCIENCE. vol. 245, 8 September 1989, LANCASTER, PA US pages 1107 - 1110; CARACCIOLO, D. ET AL.: 'Lineage-specific requirement for c-abl function in normal hematopoiesis' *
See also references of WO9103260A1 *

Also Published As

Publication number Publication date
JPH05500217A (en) 1993-01-21
AU646643B2 (en) 1994-03-03
WO1991003260A1 (en) 1991-03-21
AU6410790A (en) 1991-04-08
CA2065294A1 (en) 1991-03-02
EP0489846A1 (en) 1992-06-17

Similar Documents

Publication Publication Date Title
EP0406309A4 (en) Oligonucleotide n-alkylphosphoramidates
EP0246739A3 (en) Macrolide compounds, their preparation and their use
IL75240A (en) 1-heteroaryl-4-aryl-pyrazolin-5-ones,their preparation and their use as microbicides
EG18720A (en) Macrolide compounds, their preparation and their use
EP0489846A4 (en) Antisense oligonucleotides to c-abl proto-oncogene
EP0667778A4 (en) Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene.
GB2189324B (en) Distributor
ZA873653B (en) Dopamine-beta-hydroxylase inhibitors
PT85596A (en) Dopamine-beta-hydroxylase inhibitors
EP0580795A4 (en) Antisense oligonucleotides to c-kit proto-oncogene and uses thereof
GB9019493D0 (en) Plough
AU5086393A (en) Antisense oligonucleotides to cyclin d1 proto-oncogene
GB2177905B (en) Clothes-hanger
GB8708225D0 (en) Dosage form
GB8628239D0 (en) Spreading bar
GB2198155B (en) Improvements in knitting
GB8713642D0 (en) Plough
GB2199722B (en) Improved plough
GB8611935D0 (en) Knocking-over sinker
GB8915642D0 (en) Variant nucleotides
GB8920009D0 (en) Variant nucleotides
AU5136693A (en) Antisense oligonucleotides to b myb proto-oncogene
GB8628258D0 (en) Continuous towel cabinets
GB8526639D0 (en) Sinker bar
GB2238259B (en) Improvements in sewage distributor arms

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920508

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19940606

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19941018